Flotufolastat F-18
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Prostate Imaging-PET: 18F-Flotufolastat (Posluma).
Journal: Journal of nuclear medicine technology
Published: March 09, 2026
FDA-Approved Radiopharmaceuticals in Oncologic PET Imaging: Current Status and Clinical Impact.
Journal: American journal of clinical oncology
Published: January 14, 2026
Prostate Cancer Imaging with 18F-Flotufolastat.
Journal: Journal of nuclear medicine technology
Published: September 09, 2025
Superior Diagnostic Yield of 18F-rhPSMA-7.3 Compared With 18F-DCFPyL PET/CT for the Detection of Recurrent Prostate Cancer.
Journal: Clinical nuclear medicine
Published: September 03, 2025
Radionuclides Landscape in Prostate Cancer Theranostics.
Journal: International journal of molecular sciences
Published: June 17, 2025
Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: May 19, 2025
Evaluation of online teaching modules for PSMA PET interpretation.
Journal: The Prostate
Published: March 14, 2024
PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?
Journal: Theranostics
Published: November 26, 2023
Flotufolastat F 18: Diagnostic First Approval.
Journal: Molecular diagnosis & therapy
Published: July 06, 2023
Showing 1-10 of 10
Last Updated: 04/28/2026